TY - DATA T1 - Personalised medicine for pancreatic cancer: using endoscopic ultrasound-guided biopsy for the development of a personalised pre-clinical model of disease PY - 2019/03/27 AU - WILLIAM ARCHER BERRY UR - https://bridges.monash.edu/articles/thesis/Personalised_medicine_for_pancreatic_cancer_using_endoscopic_ultrasound-guided_biopsy_for_the_development_of_a_personalised_pre-clinical_model_of_disease/5839578 DO - 10.4225/03/5a7241a35fa4f L4 - https://ndownloader.figshare.com/files/14707325 KW - Pancreatic cancer KW - Precision medicine KW - KRAS KW - Xenograft KW - Cancer KW - Molecular Targets KW - Cancer Genetics KW - Cancer Therapy (excl. Chemotherapy and Radiation Therapy) N2 - While pancreatic cancer is a genetically heterogeneous disease, 90% of patients exhibit mutations in KRAS. Most patients also respond poorly to generalised treatments, suggesting that patient outcomes may depend on genetic profiling and personalised therapeutic approaches. A potential role for those approaches is explored here, using tumour tissue procured from patients via a minimally invasive sampling technique to test for KRAS mutation status and whether KRAS mutation influenced tumour response to treatment. Only KRAS wild-type tumours were sensitive to the drug. These techniques allow for rapid translational research, from biomarker discovery to clinical trials. ER -